| Alias | 科研级 Anti SARS-CoV-2(2019-nCoV) RBD Casirivimab(REGN10933), Anti-RBD Recombinant Antibody, Research Grade Anti SARS-CoV-2(2019-nCoV) RBD Casirivimab(REGN10933) |
| Catalog Number | YR1631 |
| Molecular Name | Anti SARS-CoV-2(2019-nCoV) RBD Casirivimab(REGN10933) |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | Human IgG |
| Formulation | PBS, pH7.5 |
| Background | Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Molecular Weight | 150 kDa |
| Target | RBD[SARS-CoV-2] |
销售微信
官方公众号
0
